Blood pro-thrombotic analytes and platelet activation are associated with post-acute sequelae of COVID-19.

Blood pro-thrombotic analytes and platelet activation are associated with post-acute sequelae of COVID-19.

Publication date: Dec 10, 2025

Post-Acute Sequelae of COVID-19 (PASC), or “long COVID,” describes persistent symptoms following recovery from SARS-CoV-2 infection. Early identification of circulating biomarkers predictive of PASC is critical for prognosis and therapeutic development yet remains poorly defined. To address this gap, we conducted a longitudinal, multi-omics analysis of blood samples from COVID-19 patients (n = 75), stratified by acute disease severity and PASC status. We integrated targeted multiplex assays, untargeted proteomics (LC-MS), and whole blood flow cytometry to define immune and vascular signatures associated with PASC. We found that individuals who went on to develop PASC exhibited a distinct phenotypic signature between 1 and 35 days post-infection, such as significantly elevated plasma Factor-IX, Tissue factor, and tPA, which reflected hyperactivation of immunothrombotic pathways. Similarly, pathway enrichment analysis revealed ongoing neutrophil degranulation, platelet activation, and extracellular matrix remodeling-indicating unresolved inflammation and immunothrombosis which persisted beyond 77 days post-symptom onset. Unlike prior studies using single biomarkers or limited timepoints, our study offers a comprehensive longitudinal analysis combining proteomic and cellular data to define a durable immune-vascular signature specific to PASC. This integrative approach reveals insights into PASC pathogenesis and highlights candidate biomarkers with potential utility in early risk stratification. Our findings underscore the critical role of chronic immune and endothelial dysfunction in long COVID and point toward actionable targets for intervention. This investigation links biorepository human samples with clinical symptoms and lays the foundation for precision diagnostics and therapeutic strategies aimed at improving long-term outcomes in COVID-19 survivors (NCT04603677).

Open Access PDF

Concepts Keywords
Covid Activation
Immunothrombosis Acute
Nct04603677 Biomarkers
Pro Blood
Remodeling Covid
Critical
Immune
Infection
Long
Pasc
Platelet
Post
Sequelae
Symptoms
Therapeutic

Semantics

Type Source Name
pathway KEGG Platelet activation
disease MESH post-acute sequelae of COVID-19
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH acute disease
disease MESH infection
drug DRUGBANK Alteplase
pathway REACTOME Neutrophil degranulation
disease MESH inflammation
disease MESH immunothrombosis
disease MESH Infectious Diseases
disease MESH Dis
pathway REACTOME Reproduction
disease MESH included
disease MESH Severe acute respiratory syndrome
disease MESH fatigue
disease MESH cognitive impairment
disease MESH dyspnea
disease MESH obesity
disease MESH asymptomatic infection
disease MESH hypoxemia
disease MESH cardiovascular diseases
disease MESH ischemic heart disease
disease MESH heart failure
disease MESH myocarditis
disease MESH convalescence
drug DRUGBANK Oxygen
disease MESH joint pain
disease MESH chest pain
disease MESH confusion
disease MESH Diabetes Mellitus
disease MESH hypertension
pathway REACTOME Digestion
drug DRUGBANK Urea
drug DRUGBANK Trypsin
drug DRUGBANK L-Lysine
drug DRUGBANK Flunarizine
disease MESH dissociation
disease MESH HCD
pathway REACTOME Release
drug DRUGBANK L-Cysteine
drug DRUGBANK Methionine
drug DRUGBANK Aspartame
disease MESH Thrombosis
disease MESH CVs

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *